Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the transaction, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Hims & Hers Health Trading Up 12.6 %
Shares of NYSE HIMS traded up $3.29 during midday trading on Wednesday, reaching $29.39. The company had a trading volume of 34,775,224 shares, compared to its average volume of 14,994,666. The business's 50-day simple moving average is $39.29 and its 200 day simple moving average is $30.23. The stock has a market cap of $6.53 billion, a P/E ratio of 66.80 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. Truist Financial boosted their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research note on Wednesday, February 26th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Leerink Partners raised their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $37.31.
Get Our Latest Research Report on HIMS
Institutional Investors Weigh In On Hims & Hers Health
Several hedge funds have recently bought and sold shares of the stock. SlateStone Wealth LLC raised its position in Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after acquiring an additional 413 shares during the period. Blume Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after acquiring an additional 628 shares during the period. Cim LLC boosted its holdings in Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company's stock valued at $1,738,000 after purchasing an additional 694 shares during the last quarter. Finally, Harbour Investments Inc. lifted its holdings in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after acquiring an additional 833 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
